DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test re-engineered immune cells to fight tough lymphomas
Disease control Recruiting nowThis early-stage study is testing a personalized cell therapy for patients with EBV-positive lymphoma that has returned or not responded to standard treatments. Researchers will collect a patient's own immune cells, modify them in a lab to better target the Epstein-Barr virus (EB…
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for Tough-to-Treat lymphoma: trial tests promising drug combo
Disease control Recruiting nowThis study is testing whether adding an experimental drug called zilovertamab vedotin to standard chemotherapy works better than standard chemotherapy alone for adults whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to…
Matched conditions: DLBCL
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Blood test could help doctors personalize lymphoma care
Disease control Recruiting nowThis study is testing if a simple blood test can help doctors better manage early-stage lymphoma. It aims to see if tracking tiny bits of tumor DNA in the blood can predict treatment success and help decide which patients need radiation. The goal is to personalize therapy to cont…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test 'Ready-Made' cell therapy for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is an early-stage safety study testing a new type of cell therapy called P-CD19CD20-ALLO1 for adults with aggressive B-cell lymphomas that have come back or not responded to standard treatments. The therapy uses genetically modified immune cells from a donor (not the patient…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for Tough-to-Treat lymphoma: adding a pill to standard chemo
Disease control Recruiting nowThis study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Scientists test new Two-Pronged attack on tough blood cancers
Disease control Recruiting nowThis is a small, early-stage study for adults with B-cell leukemia or lymphoma that has come back or not responded to other treatments. The goal is to test the safety of a new two-step approach. First, patients receive a targeted radioactive drug (131-I apamistamab), followed by …
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC
-
Landmark study seeks better paths for lymphoma patients too frail for standard care
Knowledge-focused Recruiting nowThis study aims to collect real-world information on how doctors treat patients with large B-cell lymphoma who are too frail for standard, full-dose chemotherapy or whose cancer has returned after initial treatment. By gathering data and samples from 800 patients, researchers hop…
Matched conditions: DLBCL
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC